For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and Attruby represents a true change. These novel therapies protect the transthyretin protein, preventing its harmful build-up and lessening the burden of the illness. Individuals are now experiencing benefits in their well-bei